Company intelligence / Profile preview
R3 Stem Cell
Phoenix, Arizona, United Statesr3stemcell.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
R3 Stem Cell has performed over 25,000 regenerative procedures globally with an 85% reported patient satisfaction rate. The company claims to offer safe and effective therapies using cGMP/ISO-certified biologics. It has Institutional Review Board approval for research studies in several indications and plans to commence Phase I clinical trials for opiate addiction, erectile dysfunction, knee arthritis and autism. No published peer-reviewed clinical trial results are available as of June 2025.
- Therapeutic areas
- Men's HealthPulmonologyImmunologyPsychiatryRheumatologyNeurologyCardiovascularNephrology
- Modalities
- Stem cell therapyExosome-based therapyPlatelet-rich plasma therapyPeptidesBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
None publicly disclosed with major pharmaceutical or biotech companies.
Beyond the preview
Go deeper on R3 Stem Cell.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on R3 Stem Cell.